6DUK

EGFR with an allosteric inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.190 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.

To, C.Jang, J.Chen, T.Park, E.Mushajiang, M.De Clercq, D.J.H.Xu, M.Wang, S.Cameron, M.D.Heppner, D.E.Shin, B.H.Gero, T.W.Yang, A.Dahlberg, S.E.Wong, K.K.Eck, M.J.Gray, N.S.Janne, P.A.

(2019) Cancer Discov 9: 926-943

  • DOI: 10.1158/2159-8290.CD-18-0903

  • PubMed Abstract: 
  • Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In the present study, we identify and study a mutant-selective EGFR allosteric inh ...

    Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In the present study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent, can inhibit cell proliferation and EGFR L858R/T790M/C797S signaling in vitro and in vivo. However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance. Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared to either single agent alone. Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.


    Organizational Affiliation

    Medical Oncology, Dana-Farber Cancer Institute pasi_janne@dfci.harvard.edu.,Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute.,Medical Oncology, Dana-Farber Cancer Institute.,Perlmutter Cancer Center, NYU Langone Medical Center.,Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Brigham and Women's Hospital.,Perlmutter Cancer Center, New York University Langone Medical Center.,Cancer Biology, Dana-Farber Cancer Institute.,The Translational Research Institute, The Scripps Research Institute, Scripps Florida.,Dana Farber Cancer Institutue, Department of Radiation Oncology, Harvard Medical School.,Department of Cancer Biology, Dana-Farber Cancer Institute.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Epidermal growth factor receptor
A, B, C, D, E, F
331Homo sapiensMutation(s): 2 
Gene Names: EGFR (ERBB, ERBB1, HER1)
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Go to Gene View: EGFR
Go to UniProtKB:  P00533
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ANP
Query on ANP

Download SDF File 
Download CCD File 
A, B, C, D, E, F
PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER
C10 H17 N6 O12 P3
PVKSNHVPLWYQGJ-KQYNXXCUSA-N
 Ligand Interaction
JBJ
Query on JBJ

Download SDF File 
Download CCD File 
A, B, C, D, E, F
(2R)-2-(5-fluoro-2-hydroxyphenyl)-2-{1-oxo-6-[4-(piperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindol-2-yl}-N-(1,3-thiazol-2-yl)acetamide
C29 H26 F N5 O3 S
VHQVOTINPRYDAO-AREMUKBSSA-N
 Ligand Interaction
MG
Query on MG

Download SDF File 
Download CCD File 
A, B, C, D, E, F
MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.190 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 57.481α = 70.38
b = 94.711β = 77.46
c = 97.398γ = 79.14
Software Package:
Software NamePurpose
PHASERphasing
ABSdata reduction
PHENIXrefinement
ABSdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2018-06-21 
  • Released Date: 2019-06-05 
  • Deposition Author(s): Park, E., Eck, M.J.

Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer InstituteUnited StatesR01CA201049
National Institutes of Health/National Cancer InstituteUnited StatesP01CA154303
National Institutes of Health/National Cancer InstituteUnited StatesR50CA221830

Revision History 

  • Version 1.0: 2019-06-05
    Type: Initial release
  • Version 1.1: 2019-07-17
    Type: Data collection, Database references